Canagliflozin
- Generic Name
- Canagliflozin
- Brand Names
- Invokamet, Invokana
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25FO5S
- CAS Number
- 842133-18-0
- Unique Ingredient Identifier
- 6S49DGR869
- Background
Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
...
- Indication
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
- Associated Therapies
- -
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 469
- Registration Number
- NCT01106625
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1284
- Registration Number
- NCT01106677
The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 678
- Registration Number
- NCT01081834
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 272
- Registration Number
- NCT01064414
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath